IP Library › Assignment 075120/0339
Patent Assignment
Reel/Frame 075120/0339

Assignment of Assignor's Interest

Recorded: 2026-04-13 Pages: 30
Assignor
ENDEVICA BIO, INC.
Executed: 2026-04-01
Assignee
KALOHEXIS, LLC
1935 TECHNY ROAD, SUITE 14, NORTHBROOK, ILLINOIS, 60062
Covered Properties (135)
Melanocortin Analogs Having Enhanced Activity and Transport
Application: 61/610,149 →
Melanocortin Analogs Having Enhanced Activity and Transport
Application: 15/366,112 →
Publication: US 2017/0081383
Stabilized Melanocortin Ligands
Application: 61/238,625 →
Anti-Microbial Peptides
Application: 62/052,719 →
Injectable Formulations for Non-Naturally Occurring Melanocortin Antagonist Analogs
Application: 63/704,513 →
Combination Therapies, Adjuvants, and Methods of Treating Cancer Using the Same
Application: 63/486,160 →
Combination Therapies, Adjuvants, and Methods of Treating Cancer Using the Same
Application: 63/497,580 →
Methods of Treating Cancer and/or Chemotherapy Related Conditions Using Non-Naturally Occurring Melanocortin Analogs
Application: 63/514,212 →
Methods of Treating Cancer and/or Chemotherapy Related Conditions Using Non-Naturally Occurring Melanocortin Analogs
Application: 63/618,587 →
Methods of Treating Cancer and/or Chemotherapy Related Conditions Using Non-Naturally Occuring Melanocortin Analogs
Application: 19/158,032 →
Methods of Stimulating Appetite and/or Increasing Body Weight in Subjects Having a Fibrotic Disease Using Non-Naturally Occurring Melanocortin Analogs
Application: 63/486,232 →
Methods of Stimulating Appetite and/or Increasing Body Weight in Subjects Having a Fibrotic Disease Using Non-Naturally Occurring Melanocortin Analogs
Application: 63/541,394 →
Methods of Stimulating Appetite and/or Increasing Body Weight in Subjects Having a Fibrotic Disease Using Non-Naturally Occurring Melanocortin Analogs
Application: 19/158,013 →
Methods of Increasing Body Weight and/or Food Intake in a Subject Having an Unchallenged Metabolism and Associated Compositions
Application: 63/418,468 →
Methods of Stimulating Appetite and/or Increasing Body Weight Using Non-Naturally Occurring Melanocortin Analogs
Application: 63/486,169 →
Methods of Stimulating Appetite and/or Increasing Body Weight Using Non-Naturally Occurring Melanocortin Analogs
Application: 63/497,597 →
Methods of Stimulating Appetite and/or Increasing Body Weight Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs
Application: 19/183,258 →
Publication: US 2026/0098072
Combination Therapies Comprising Non-Naturally Occurring Melanocortin Analogs and Methods of Using the Same
Application: 63/485,867 →
Combination Therapies Comprising Non-Naturally Occurring Melanocortin Analogs and Methods of Using the Same
Application: 63/453,664 →
Combination Therapies Comprising Non-Naturally Occurring Melanocortin Analogs and Methods of Using the Same
Application: 63/514,271 →
Methods of Preventing and/or Treating Side Effects Associated with Anti-Cancer Agents Using Non-Naturally Occurring Melanocortin Analogs with Anti-Gdf-15 Antibodies
Application: 19/157,332 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Glp-1 Agonists and Associated Methods
Application: 63/607,500 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Glp-1 Agonists and Associated Methods
Application: 63/618,843 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Glp-1 Agonists and Associated Methods
Application: 63/557,385 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Glp-1 Agonists and Associated Methods
Application: 63/573,429 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Glp-1 Agonists and Associated Methods
Application: 63/650,705 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Glp-1 Agonists and Associated Methods
Application: 63/656,583 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Glp-1 Agonists and Associated Methods
Application: 63/663,648 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/554,944 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/654,876 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/656,579 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/663,689 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/675,219 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/681,055 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/692,605 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/557,409 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/572,896 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/573,433 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/632,496 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/637,285 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/640,864 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/647,545 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/650,368 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/656,574 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/663,663 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/675,181 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/681,082 →
Orally Deliverable Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/692,552 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/650,395 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/654,885 →
Non-Naturally Occurring Melanocortin Receptor Analogs and Associated Methods
Application: 63/683,628 →
Non-Naturally Occurring Melanocortin Receptor Agonists and Use Therefore in Treatment of Addiction and/or Pain
Application: 63/650,909 →
Non-Naturally Occurring Melanocortin Receptor Agonists and Use Therefore in Treatment of Addiction and/or Pain
Application: 63/654,891 →
Non-Naturally Occurring Melanocortin Receptor Agonists and Use Therefore in Treatment of Addiction and/or Pain
Application: 63/655,556 →
Non-Naturally Occurring Melanocortin Receptor Agonists and Use Therefore in Treatment of Addiction and/or Pain
Application: 63/711,605 →
Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs with N-Terminal Extension
Application: 63/683,633 →
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs with N-Terminal Extension
Application: 63/683,637 →
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs with Fluorinated Dphe and N-Terminal Extension
Application: 63/683,645 →
Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs with C-Terminal Extension
Application: 63/683,651 →
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs with C-Terminal Extension
Application: 63/683,658 →
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs with Fluorinated Dphe and C-Terminal Extension
Application: 63/683,666 →
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs with Expanded Cycle
Application: 63/683,669 →
Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs with Various Lactam Cyclization Types
Application: 63/683,671 →
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs with Various Lactam Cyclization Types
Application: 63/683,676 →
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs with Halogenated Dphe and Various Lactam Cyclization Types
Application: 63/683,679 →
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Receptor Agonist Analogs
Application: 63/704,516 →
Injectable Formulations for Non-Naturally Occurring Melanocortin Antagonist Analogs
Application: 63/704,508 →
Injectable Formulations for Non-Naturally Occurring Melanocortin Agonist Analogs
Application: 63/704,502 →
Injectable Formulations for Non-Naturally Occurring Melanocortin Agonist Analogs
Application: 63/704,486 →
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Receptor Agonist Analogs
Application: 63/704,519 →
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Receptor Agonist Analogs
Application: 63/759,025 →
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs
Application: 63/759,023 →
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Receptor Agonist Analogs
Application: 63/759,020 →
Formulations for Oral Administration of Non-Naturally Occurring Melanocortin Receptor Analogs
Application: 63/759,024 →
Melanocortin Analogs Having Enhanced Activity and Transport
Patent: 9,534,018 →
Application: 14/384,694 →
Publication: US 2015/0045293
Stablized Melanocortin Ligands
Patent: 8,541,545 →
Application: 13/389,820 →
Publication: US 2012/0220525
Anti-Microbial Peptides
Application: 15/511,669 →
Publication: US 2017/0247414
Anti-Microbial Peptides
Application: 16/418,127 →
Publication: US 2020/0109171
Melanocortin Analogs Having Enhanced Activity and Transport
Stabilized Melanocortin Ligands
Anti-Microbial Peptides
Injectable Formulations for Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs for Modulating Weight Gain
Methods of Treating Cancer and/or Chemotherapy Related Conditions Using Non-Naturally Occurring Melanocortin Analogs
Methods of Stimulating Appetite and/or Increasing Body Weight in Subjects Having a Fibrotic Disease Using Non-Naturally Occurring Melanocortin Analogs
Methods of Stimulating Appetite and/or Increasing Body Weight Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs
Methods of Preventing and/or Treating Side Effects Associated with Anti-Cancer Agents Using Non-Naturally Occurring Melanocortin Analogs with Anti-Gdf-15 Antibodies
Non-Naturally Occurring Melanocortin Analogs and Uses Thereof for Modulating Weight Gain
Non-Naturally Occurring Melanocortin Analogs and Associated Methods for Modulating Weight Gain
Non-Naturally Occurring Melanocortin Analogs and Uses Thereof for Treating Substance Use Disorders
Non-Naturally Occurring Melanocortin Analogs and Associated Methods
Methods of Treating Cancer and/or Chemotherapy Related Conditions Using Non-Naturally Occurring Melanocortin Analogs
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs and Uses Thereof for Modulating Weight Loss
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs and Associated Methods for Modulating Weight Gain
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs and Uses Thereof for Treating Substance Use Disorders
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs and Uses Thereof for Modulating Weight Loss
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs and Associated Methods for Modulating Weight Gain
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs and Uses Thereof for Treating Substance Use Disorders
Orally Deliverable Non-Naturally Occurring Melanocortin Analogs
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs for Modulating Weight Loss
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs for Modulating Weight Gain
Non-Naturally Occurring Melanocortin Receptor Agonist Analogs for User in Pain Management and/or Substance Use Disorders
Non-Naturally Occurring Melanocortin Receptor Agonists and Uses Thereof for Modulating Weight Loss
Non-Naturally Occurring Melanocortin Receptor Agonists and Uses Thereof for Modulating Weight
Non-Naturally Occurring Melanocortin Receptor Agonists and Use Therefore in Treatment of Addiction and/or Pain
Non-Naturally Occurring Melanocortin Analogs and Uses Thereof
Non-Naturally Occurring Melanocortin Analogs with an N-Terminal Extension for Modulating Weight Gain
Non-Naturally Occurring Melanocortin Analogs with an N-Terminal Extension for Modulating Diabetes and/or Treating Substance Use Disorders
Non-Naturally Occurring Melanocortin Analogs with an N-Terminal Extension for Modulating Weight Loss
Non-Naturally Occurring Melanocortin Analogs with an Extended C-Terminus for Modulating Weight Gain
Non-Naturally Occurring Melanocortin Analogs with an Extended C-Terminus for Modulating Diabetes and/or Treating Substance Use Disorders
Non-Naturally Occurring Melanocortin Analogs with an Extended C-Terminus for Modulating Weight Loss
Non-Naturally Occurring Melanocortin Analogs with an Expanded Cycle for Modulating Weight Loss
Non-Naturally Occurring Melanocortin Analogs with Various Lactam Cyclization Types for Modulating Weight Gain
Non-Naturally Occurring Melanocortin Analogs with Halogenated Dphe and Various Lactam Cyclization Types for Modulating Diabetes and/or Treating Substance Use Disorders
Non-Naturally Occurring Melanocortin Analogs with Various Lactam Cyclization Types for Modulating Weight Loss
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Receptor Agonist Analogs for Modulating Weight Loss
Injectable Formulations for Non-Naturally Occurring Melanocortin Antagonist Analogs for Modulating Weight Gain
Injectable Formulations for Non-Naturally Occurring Melanocortin Receptor Agonist Analogs for Modulating Weight Loss
Injectable Formulations for Non-Naturally Occurring Melanocortin Analogs for Treating Substance Use Disorders and/or Modulating Diabetes
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Analogs for Treating Substance Use Disorders and/or Modulating Diabetes
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Analogs for Modulating Weight Loss
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Analogs
Non-Naturally Occurring Melanocortin Analogs with Various Lactam Cyclization Types and Associated Uses
Non-Naturally Occurring Melanocortin Analogs with Expanded Cycles and/or Extended Termini and Associated Uses
Non-Naturally Occurring Melanocortin Analogs with an Expanded Cycle for Modulating Diabetes or Treating Substance Use Disorders
Injectable Formulations for Non-Naturally Occurring Melanocortin Analogs
Injectable Formulations for Non-Naturally Occurring Melanocortin Analogs for Modulating Weight Loss
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Analogs for Treating Substance Use Disorders and/or Modulating Diabetes
Injectable Formulations for Non-Naturally Occurring Melanocortin Analogs for Treating Substance Use Disorders and/or Modulating Diabetes
Non-Naturally Occurring Melanocortin Analogs with Expanded Cycles and/or an Extended N-Terminus for Modulating Gastrointestinal Disorders
Non-Naturally Occurring Melanocortin Analogs with Various Cyclization Types and/or Extended Termini for Modulating Kidney Function and/or Glucose Uptake
Non-Naturally Occurring Melanocortin Analogs with Various Lactam Cyclization Types for Modulating Gastrointestinal Disorders
Injectable Formulations for Non-Naturally Occurring Melanocortin Analogs for Modulating Kidney Function and/or Glucose Uptake
Formulation for Oral Administration of Non-Naturally Occurring Melanocortin Analogs for Modulating Kidney Function and/or Glucose Uptake
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 11, 2012
From: GRUBER, KENNETH A
To: TENSIVE CONTROLS, INC.
Reel/Frame 028932/0088 →
Assignment of Assignor's Interest Jun 19, 2018
From: GRUBER, KENNETH A.
To: TENSIVE CONTROLS, INC.
Reel/Frame 046124/0603 →
Assignment of Assignor's Interest Nov 23, 2022
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO
Reel/Frame 061864/0960 →
Corrective Assignment to Correct the Assignee's Name on the Assignment Document from Endevica Bio to Endevica Bio, Inc. Previously Recorded on Reel 061864 Frame 0960. Assignor(S) Hereby Confirms the Assignment. Mar 8, 2023
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 062998/0153 →
Change of Name Mar 8, 2023
From: TENSIVE CONTROLS, INC.
To: ENDEVICA BIO, INC.
Reel/Frame 063013/0670 →
Assignment of Assignor's Interest Mar 8, 2023
From: GRUBER, KENNETH A.
To: TENSIVE CONTROLS, INC.
Reel/Frame 063010/0241 →
Assignment of Assignor's Interest Mar 8, 2023
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 062919/0186 →
Change of Name Mar 22, 2023
From: TENSIVE CONTROLS, INC.
To: ENDEVICA BIO, INC.
Reel/Frame 063146/0245 →
Assignment of Assignor's Interest Mar 22, 2023
From: GRUBER, KENNETH A.
To: TENSIVE CONTROLS, INC.
Reel/Frame 063058/0059 →
Assignment of Assignor's Interest Mar 29, 2023
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 063150/0150 →
Change of Name Apr 5, 2023
From: TENSIVE CONTROLS, INC.
To: ENDEVICA BIO, INC.
Reel/Frame 063264/0967 →
Assignment of Assignor's Interest May 3, 2023
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 063519/0652 →
Assignment of Assignor's Interest Jun 12, 2023
From: ZHU, XINXIA; MARKS, DANIEL
To: OREGON HEALTH & SCIENCE UNIVERSITY
Reel/Frame 063919/0785 →
Assignment of Assignor's Interest Aug 10, 2023
From: ZHU, XINXIA; MARKS, DANIEL
To: OREGON HEALTH & SCIENCE UNIVERSITY
Reel/Frame 064548/0876 →
Assignment of Assignor's Interest Aug 14, 2023
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 064579/0983 →
Assignment of Assignor's Interest Sep 1, 2023
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 064772/0701 →
Assignment of Assignor's Interest Nov 28, 2023
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 065687/0029 →
Assignment of Assignor's Interest Feb 8, 2024
From: DELEV, JORDAN
To: ENDEVICA BIO, INC.
Reel/Frame 066416/0094 →
Assignment of Assignor's Interest Feb 14, 2024
From: POTTERFIELD, RUSSELL; DELEV, JORDAN
To: ENDEVICA BIO, INC.
Reel/Frame 066463/0085 →
Assignment of Assignor's Interest Feb 14, 2024
From: POTTERFIELD, RUSSELL
To: ENDEVICA BIO, INC.
Reel/Frame 066462/0591 →
Assignment of Assignor's Interest Dec 6, 2024
From: POTTERFIELD, RUSSELL; DELEV, JORDAN
To: ENDEVICA BIO, INC.
Reel/Frame 069507/0813 →
Assignment of Assignor's Interest Dec 11, 2024
From: POTTERFIELD, RUSSELL; DELEV, JORDAN
To: ENDEVICA BIO, INC.
Reel/Frame 069553/0362 →
Assignment of Assignor's Interest Dec 11, 2024
From: POTTERFIELD, RUSSELL; DELEV, JORDAN
To: ENDEVICA BIO, INC.
Reel/Frame 069553/0831 →
Assignment of Assignor's Interest Dec 11, 2024
From: POTTERFIELD, RUSSELL; DELEV, JORDAN
To: ENDEVICA BIO, INC.
Reel/Frame 069554/0600 →
Assignment of Assignor's Interest Dec 11, 2024
From: POTTERFIELD, RUSSELL; DELEV, JORDAN; BADEAU, BARRY ALICK
To: ENDEVICA BIO, INC.
Reel/Frame 069555/0048 →